Helicobacter pylori infection in childhood: Results of management with ranitidine bismuth citrate plus amoxicillin and tinidazole

Abstract

Findings suggest that the present treatment regimen is effective enough in the resolution of H. pylori-associated peptic ulcer disease of childhood.

Systematic Review and Meta‐analysis: Proton Pump Inhibitor vs. Ranitidine Bismuth Citrate Plus Two Antibiotics in Helicobacter pylori Eradication

“…With the predefined search strategy, 202 articles were retrieved from MEDLINE and 332 from EMBASE. Included studies assessing H. pylori eradication with RBC plus two antibiotics are summarized in Table 1[3–94].…”

Nifuratel-Containing Initial Anti-Helicobacter pyloriTriple Therapy in Children

“…Biopsy samples were fixed in 10% buffered formalin, processed, embedded in paraffin, and cut into 5 µm sections. The slides were stained with standard haematoxylin and eosin (H&E) and modified Giemsa staining to estimate gastric inflammation score and H. pylori presence and density [4,19]. The score of gastritis severity and the density of H. pylori colonization of gastric mucosa were assessed according to the Mitchell's grading system [22].…”

“…Helicobacter pylori infection is the main etiologic factor in chronic gastritis in childhood [1][2][3]. Eradication of H. pylori results in healing of H. pylori gastritis [3,4]. Randomized clinical trials have tested proton pump inhibitor (PPI)containing triple-eradication regimens with two antibiotics and these are the usual treatments of choice for H. pylori infection [5,6].…”

Choosing Optimal Firstline Helicobacter pylori Therapy: a View from a Region with High Rates of Antibiotic Resistance

“…However, they remain effective in areas where resistance remains low [25]. Ranitidine bismuth-citrate in combination with amoxicillin and tinidazole also proved effective including in Russian children [26]. …”

“…Subsequent studies in other regions with higher rates of metronidazole resistance such as Taiwan, Korea, Panama, Spain, Poland, Thailand, and India have shown it to be relatively ineffective ( e.g. , treatment success of 80% or less) [26, 52–56] and it should be considered obsolete except in regions with low rates of metronidazole resistance. In any area where clarithromycin and metronidazole resistance are present but not high (e.g., metronidazole resistance <20%), 14-day concomitant will be superior to sequential therapy.…”